User profiles for Tanaya Siripoon
 | Tanaya SiripoonVerified email at mahidol.edu Cited by 152 |
[HTML][HTML] Strongyloides stercoralis: A Neglected but Fatal Parasite
V Luvira, T Siripoon, D Phiboonbanakit… - Tropical Medicine and …, 2022 - mdpi.com
Strongyloidiasis is a disease caused by Strongyloides stercoralis and remains a neglected
tropical infection despite significant public health concerns. Challenges in the management …
tropical infection despite significant public health concerns. Challenges in the management …
[HTML][HTML] Efficacy and safety of immunomodulators in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials
…, N Ruenroegnboon, V Luvira, T Siripoon… - Infectious Diseases and …, 2022 - Springer
Introduction Many immunomodulators have been studied in clinical trials for the treatment of
coronavirus disease 2019 (COVID-19). However, data identifying the most effective and …
coronavirus disease 2019 (COVID-19). However, data identifying the most effective and …
[HTML][HTML] Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2 …
…, JA Watson, S Boyd, V Luvira, T Siripoon… - The Lancet Infectious …, 2024 - thelancet.com
Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19
antiviral treatments, but their antiviral activities in patients have not been compared …
antiviral treatments, but their antiviral activities in patients have not been compared …
[HTML][HTML] High mobility group box 1 and interleukin 6 at intensive care unit admission as biomarkers in critically ill COVID-19 patients
…, P Wattanawinitchai, T Siripoon… - The American Journal …, 2021 - ncbi.nlm.nih.gov
Exuberant inflammation manifesting as a “cytokine storm” has been suggested as a central
feature in the pathogenesis of severe coronavirus disease 2019 (COVID-19). This study …
feature in the pathogenesis of severe coronavirus disease 2019 (COVID-19). This study …
Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV)
…, JA Watson, V Luvira, T Siripoon… - The Journal of …, 2023 - academic.oup.com
Background Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …
[HTML][HTML] Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
…, P Jittamala, JA Watson, S Boyd, T Siripoon… - BMC Infectious …, 2024 - Springer
Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral …
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral …
Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)
…, P Jittamala, JA Watson, M Ekkapongpisit, T Siripoon… - ELife, 2023 - elifesciences.org
Background: There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment …
activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment …
[HTML][HTML] Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis …
…, P Jittamala, S Boyd, V Luvira, T Siripoon… - The Lancet Infectious …, 2024 - thelancet.com
Background Effective antiviral drugs prevent hospitalisation and death from COVID-19.
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …
[HTML][HTML] Temporal trend of COVID-19 vaccine acceptance and factors influencing international travellers
…, S Lawpoolsri, P Pisutsan, T Siripoon… - Tropical Medicine and …, 2022 - mdpi.com
The COVID-19 pandemic has seen disrupted international travel due to travel restrictions
and public health measures aimed at containing the spread of the virus. With increasing …
and public health measures aimed at containing the spread of the virus. With increasing …
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants
Background Uncertainty over the therapeutic benefit provided by parenteral remdesivir in
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …
